Prostate cancer, the most common cancer in men in Western societies, was until recently considered a taboo disease, because it was associated with the sexual potency of a man.  However, we have now achieved its radical treatment with minimally invasive methods that do not affect the sexual function of the patient.

The booming technological advances have led to the new era of stereotactic radiotherapy or radiosurgery. Its accuracy has reached a level of millimeters.

We treat prostate cancer bloodlessly and effectively, preserving the quality of life of the patient. The important thing is that radiotherapy also treats now successfully high risk patients with locally advanced disease. Our success rates are as high as those of surgical procedures, regardless of the stage, the age and the anatomical particularities of the patient.

Stereotactic radiotherapy of locally detected prostate cancer is the new emerging treatment method. It offers high targeting and precision, with high-dose irradiation in a short period of time, of approximately five to seven days, instead of the 35 days required for classical radiotherapy. It offers comparable results with low and controllable side effects.

A new treatment perspective for locally detected cancer is offered by the partial (focal) irradiation of the prostate, which has fewer side effects (it minimizes the symptoms of dysuria such as tingling, frequent urination, etc.).

The combination of classical radiotherapy and brachytherapy, offers patients with locally advanced disease or high-risk disease, the highest success rates compared to any other single treatment, which are comparable to the ones of patients with low-risk or early stage disease.

Another important indication of radiotherapy is when patients who have undergone radical prostatectomy experience a biochemical recurrence (that is a raise in PSA levels); in this case we offer them a second chance of cure with radical/classical post-operative radiotherapy.

Patients who recovered from prostate cancer are increasing rapidly. They want not only to “survive” but to “live”. If they had a healthy sex life before the manifestation of the disease, they have a better chance of coming back to it after their treatment.

If prostate cancer is diagnosed early, the five-year survival rate of the patient is close to 100%. It is optimistic that more and more men are undergoing preventive examinations, which results in increased early diagnosis rates, and thus in increased rates of radical recovery from prostate cancer. Preventive tests are essential because prostate cancer does not show any symptoms in its early stages.

After the age of fifty, men should visit their urologist once a year as a preventive measure. PSA is now a routine test which, in 70% of patients, detects the disease at an early stage, therefore the survival expectancy is very high. The PSA test in combination with the digital rectal examination, transrectal ultrasound, multiparametric magnetic resonance imaging and targeted biopsy helps staging the disease and making the right treatment decisions.

We have modern equipment, know-how and we provide safe treatments with low side effects. I am fortunate to operate state-of-the-art equipment, that offers my patients the best results with the lowest possible side effects. Cancer is no longer an incurable disease. Since the 1970s, the patients who recovered from cancer have increased sixfold globally.

Radiotherapy is the most personalized treatment because it is designed and carried out according to the needs of each patient.

We are here to offer treatment and care, individually for each patient.